Amrutanjan Health Care is expanding its distribution to reach 100,000 direct chemist outlets by FY27 to become a national player. While the company reported strong FY26 growth, investors are monitoring a sharp decline in Q1 FY27 net profit caused by higher costs and category softness.
Amrutanjan Health Care is working to transform its business from a regional powerhouse into a national brand. The company has set a strategic target to reach 100,000 direct chemist outlets across India by the end of the 2027 fiscal year. This expansion is designed to reduce the company's dependence on its traditional strongholds in Southern and Eastern India and tap into a wider customer base.
Financial Performance and Recent Pressures
The company’s path to growth currently faces a mixed financial picture. In the full fiscal year 2026, Amrutanjan delivered solid performance, with revenue from operations rising 11.23% to ₹502.55 crore and net profit increasing by nearly 14% to ₹57.92 crore. However, the first quarter of fiscal year 2027 revealed new challenges. While revenue grew 9.48% to ₹102.97 crore, net profit fell by 47.41% to ₹4.37 crore.
This drop in profitability has been linked to a few specific factors. The company faced a one-time lease-related provision of ₹2.03 crore, which impacted the bottom line. Additionally, management noted a softness in demand within the pain management category and a change in the product mix. Increased spending on marketing and the expansion of the distribution network have also placed pressure on short-term margins.
Investment in Manufacturing and Brands
To support its long-term goals, Amrutanjan has been investing heavily in infrastructure. The company commissioned a ₹150 crore manufacturing facility in Telangana specifically for its sanitary napkin brand, Comfy. This move is part of a broader strategy to scale up production and compete more effectively in the hygiene products market. Beyond physical products, the company is also looking to revitalize its 'Relief' congestion-management brand, aiming to create new revenue streams to balance its core portfolio.
Risks and Market Context
One of the company's core strengths is its balance sheet, as it remains virtually debt-free. This provides financial flexibility even when profits face temporary pressure. However, the healthcare consumer goods sector in India remains highly competitive. The company’s heavy reliance on the pain management segment makes it vulnerable when demand in that specific category slows down. Furthermore, the cost of scaling up to 100,000 outlets is significant. Investors will likely watch whether the increased distribution reach leads to sustained sales growth that can eventually offset these higher operating costs and restore profit margins. The main monitorables for shareholders will be the recovery in profit margins, the success of the new manufacturing unit in scaling up hygiene products, and whether the distribution expansion translates into higher demand in the coming quarters.